© 2022 NewsICAN – Latest and Exclusive News World
It is time for buyers to promote shares of Quest Diagnostics , based on Citi. Analyst Patrick Donnelly downgraded shares of the medical testing firm to promote from impartial, citing dangers forward to the corporate earnings per share steering and 4% to five% long-term progress information for its base enterprise. “While management has continued to reiterate the $8.50 earnings number for FY23, even if we give the company credit for hitting this, we see the multiple as inflated and at risk for compression,”…